Skip to main content

Table 1 Baseline patients characteristics

From: Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study

Parameter (units)

Safety population (N = 126)

ITT population (N = 125)

PP population (N = 116)

Age (years), mean ± SD

68.75 ± 8.64

68.65 ± 8.61

68.69 ± 8.61

Height (cm), mean ± SD

159.91 ± 9.72

160.11 ± 9.50

159.97 ± 9.34

Weight (kg), mean ± SD

63.52 ± 9.90

63.60 ± 9.90

63.45 ± 9.54

BMI (kg/m2), mean ± SD

24.94 ± 4.16

24.91 ± 4.15

24.90 ± 4.11

Gender, n (%)

 Female

35 (27.78)

35 (28)

32 (27.59)

 Male

91 (72.22)

90 (72)

84 (72.41)

Study eye, n (%)

 Left

51 (40.48)

50 (40)

46 (39.66)

 Right

75 (59.52)

75 (60)

70 (60.34)

  1. BMI body mass index, ITT intent-to-treat, PP per-protocol, SD standard deviation